Ignite Creation Date:
2025-12-24 @ 3:45 PM
Ignite Modification Date:
2025-12-25 @ 5:03 PM
Study NCT ID:
NCT05903092
Status:
RECRUITING
Last Update Posted:
2025-05-04
First Post:
2023-06-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Sponsor:
Hirva Mamdani
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-26
Start Date Type:
ACTUAL
Primary Completion Date:
2026-01-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-01-03
Completion Date Type:
ESTIMATED
First Submit Date:
2023-06-05
First Submit QC Date:
None
Study First Post Date:
2023-06-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-01
Last Update Post Date:
2025-05-04
Last Update Post Date Type:
ACTUAL